Scalper1 News
Gilead Sciences (GILD) reported more positive data from its hepatitis C drug pipeline Wednesday, sending shares up 2% in the stock market today . The data came from three phase-three studies using the recently approved drug sofosbuvir with candidate ledipasvir in patients with genotype 1 of the virus, the most common type. The sustained response rate was well above 90% in all patient groups. Analysts noted that, except among patients who failed Scalper1 News
Scalper1 News